Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Healthcare Biotechnology
Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > !!! ALL TIMELINES FLASHING IMMINENT !!!
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(625)
•••
Comment by KayakerBCon Dec 10, 2022 5:50pm
127 Views
Post# 35164159

RE:!!! ALL TIMELINES FLASHING IMMINENT !!!

RE:!!! ALL TIMELINES FLASHING IMMINENT !!!I just got back from a bike ride.  The only things flashing were my bike lights.

Further to my last prediction, I'm expecting you'll pump it like this going into news on Tuesday, sell on the news, disappear for a week or two, and be back bashing all things Bioasis. 

Here's some stuff you posted back in your digitel days.  Feel free to cut and paste as needed.

"....BTI is still a pre-clinical story too. It's highly speculative....Highly speculative assets can get crushed...."

"....The company is much closer to its 52-week low than its high of last year. Has the company experienced negative validation as it runs low on cash and into tax loss selling?...."

"....When bagholders are excited doesn't that mean they are about to get another bag to hold? Are the new insiders excited given the number of shares they've bought since joining? I wonder how many companies have less skin in the game than BTI 2.0?...."
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities